Innoviva Specialty Therapeutics
Biotechnology, 35 Gatehouse Drive, Waltham, , 2451, Massachusetts, United States, 51-200 Employees
Phone Number: +18*********
Who is INNOVIVA SPECIALTY THERAPEUTICS
Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious diseas...
Read More
-
Headquarters: 35 Gatehouse Drive, Waltham, Massachusetts, 2451, United States
-
Date Founded: 2023
-
Employees: 51-200
-
Revenue: $25 Million to $50 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from INNOVIVA SPECIALTY THERAPEUTICS
Innoviva Specialty Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Innoviva Specialty Therapeutics
Answer: Innoviva Specialty Therapeutics's headquarters are located at 35 Gatehouse Drive, Waltham, , 2451, Massachusetts, United States
Answer: Innoviva Specialty Therapeutics's phone number is +18*********
Answer: Innoviva Specialty Therapeutics's official website is https://innovivaspecialtytherapeutics.com
Answer: Innoviva Specialty Therapeutics's revenue is $25 Million to $50 Million
Answer: Innoviva Specialty Therapeutics's SIC: 2834
Answer: Innoviva Specialty Therapeutics's NAICS: 541714
Answer: Innoviva Specialty Therapeutics has 51-200 employees
Answer: Innoviva Specialty Therapeutics is in Biotechnology
Answer: Innoviva Specialty Therapeutics contact info: Phone number: +18********* Website: https://innovivaspecialtytherapeutics.com
Answer: Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc., is a biopharmaceutical company developing and delivering innovative therapies in critical care and infectious disease. Our approved treatments are indicated for use in life-threatening circumstances for seriously ill patients, and our investigational therapies are in development for patients fighting drug-resistant pathogens. Growing antimicrobial resistance to existing therapies represents an urgent threat to global public health, and is directly related to significant mortality rates and longer, more expensive hospital stays. We are proud to work with physicians, nurses, hospital pharmacists and administrators, and all who devote their time to caring for patients.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month